Abstract:Background The triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario present the mainstay in TNBC treatment, paclitaxel resistance is still a striking obstacle for cancer cure. So it is imperative to probe new therapeutic targets through illustrating the mechanisms underlying paclitaxel chemoresistance. Methods The Single cell RNA sequencing (scRNA-seq) data of TNBC cells treated with paclitaxel at different points were downloaded from the Gene Expression Omnibus (GEO) database. The Seurat R package was used to filter and integrate the scRNA-seq expression matrix. Cells were further clustered by the FindClusters function, and the gene marker of each subset was defined by FindAllMarkers function. Then, the hallmark score of each cell was calculated by AUCell R package, the biological function of the highly expressed interest genes was analyzed by the DAVID database. Subsequently, we performed pseudotime analysis to explore the change patterns of drug resistance genes and SCENIC analysis to identify the key transcription factors (TFs). Finally, the inhibitors of which were also analyzed by the CTD database. Results We finally obtained 6 cell subsets from 2798 cells, which were marked as AKR1C3+, WNT7A+, FAM72B+, RERG+, IDO1+ and HEY1+HCC1143 cell subsets, among which the AKR1C3+, IDO1+ and HEY1+ cell subsets proportions increased with increasing treatment time, and then were regarded as paclitaxel resistance subsets. Hallmark score and pseudotime analysis showed that these paclitaxel resistance subsets were associated with the inflammatory response, virus and interferon response activation. In addition, the gene regulatory networks (GRNs) indicated that 3 key TFs (STAT1, CEBPB and IRF7) played vital role in promoting resistance development, and five common inhibitors targeted these TFs as potential combination therapies of paclitaxel were identified. Conclusion In this study, we identified 3 paclitaxel resistance relevant IFs and their inhibitors, which offers essential molecular basis for paclitaxel resistance and beneficial guidance for the combination of paclitaxel in clinical TNBC therapy.

Research Progress in Chemoresistance Mechanism of Paclitaxel and the Future Direction

Establishment of a new paclitaxel resistant cell line of human ovarian carcinoma and preliminary observation of its biology.

Exploration and Outlook of Recent Applications of Paclitaxel in Breast Cancer Treatment

Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance.

Key genes and molecular mechanisms related to Paclitaxel Resistance

Progress in research on paclitaxel and tumor immunotherapy

Lin28 Mediates Paclitaxel Resistance By Modulating P21, Rb And Let-7a Mirna In Breast Cancer Cells

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis

Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer

Resistance to Intervention: Paclitaxel in Breast Cancer

Mechanisms of Taxane Resistance

Emerging Nanomedicines of Paclitaxel for Cancer Treatment

Progress in research of antineoplastic taxane

Medicinal Chemistry of Paclitaxel and Its Analogues

MicroRNAs: Key Players of Taxane Resistance and Their Therapeutic Potential in Human Cancers

Advances of Src Kinase Family and Paclitaxel Resistance

Progress in Carriers of Anticancer Paclitaxel

Advances Research in Mechanism of Antitumor Activity of Taxanes

Progress on the Prodrugs of Paclitaxel

The resistance mechanism and response prediction of docetaxel

Integrating transcriptomics, proteomics, glycomics and glycoproteomics to characterize paclitaxel resistance in breast cancer cells